Results 151 to 160 of about 55,552 (271)

Is a Prior History of PCI a Predictor of MACE Within 1 Year of CABG, a Propensity‐Matched Analysis Using Optimal Matching

Journal of Cardiac Surgery, Volume 2026, Issue 1, 2026.
Background Percutaneous coronary intervention (PCI) is an effective option for myocardial revascularization, even for high‐risk patients. As a result, more patients who undergo coronary artery bypass grafting (CABG) have previously had PCI. This study aims to assess the impact of prior PCI on the occurrence of major adverse cardiac events (MACEs ...
Hani N. Mufti, Fahad Alshair, Anas Alqahtani, Omar Alqahtani, Mohammed Alfaqih, Abdullah Alsaedi, Eisa Sanai, Luis Acosta, Marco Piciche   +8 more
wiley   +1 more source

The Twelve-Month Outcome of Biolimus Eluting Stent with Biodegradable Polymer Compared With an Everolimus Eluting Stent with Durable Polymer

Journal of Cardiovascular and Thoracic Research, 2011
Introduction: Drug-eluting stents (DES) have significantly decreased the need for repeat coronary revascularization but concerns remain regarding the safety of first and second generation DES.
Ahmad Separham, Bahram Sohrabi, Naser Aslanabadi, Samad Ghaffari   +3 more
doaj   +1 more source

Predictors of Outcome in The Treatment of In-Stent Restenosis with Drug-Eluting Balloons

, 2022
Noor Faraz, Abdul Qadir Bhutto, Imran Ellahi Soomroo, Jabir Hasan Khan, Muhammad Nawaz, Muhammad Humza   +5 more
openalex   +2 more sources

Drug-Eluting Balloon: An Overview of Clinical Evidences on Safety and Effectiveness

Journal of Pharmacoeconomics and Pharmaceutical Management, 2015
Background: Recent advances in the intravascular diseases have led to the entrance of drug-eluting balloon (DEB) technology. The DEB is a relatively new and easier way to treat vascular stenosis.
Khosro Keshavarz, Amir Hashemi-Meshkini, Pardis Zaboli, Jamal Khedmati, Abbas Kebriaeezadeh   +4 more
doaj  

Identification of endothelial protein C receptor as a novel druggable agonistic target for reendothelialization promotion and thrombosis prevention of eluting stent

Bioactive Materials
The commercially available drug-eluting stent with limus (rapamycin, everolimus, etc.) or paclitaxel inhibits smooth muscle cell (SMC), reducing the in-stent restenosis, whereas damages endothelial cell (EC) and delays stent reendothelialization ...
Jing Chen, Changyi Zhou, Weilun Fang, Jiasheng Yin, Jian Shi, Junbo Ge, Li Shen, Shi-Ming Liu, Shao-Jun Liu   +8 more
doaj   +1 more source

Recent advances in drug eluting stents

, 2012
Amey S. Puranik, Eileen R. Dawson, Nicholas A. Peppas   +2 more
openalex   +2 more sources

Risk investigation of in-stent restenosis after initial implantation of intracoronary drug-eluting stent in patients with coronary heart disease [PDF]

, 2023
Hongfei Xi, Jiasi Liu, Tao Xu, Zhe Li, Xuanting Mou, Yu Jin, Shudong Xia   +6 more
openalex   +1 more source

Computational design of artificial organs [PDF]

, 2008
C
De Beule, Matthieu, Verdonck, Pascal
core   +1 more source

Characterisation of the mechanobiology of stents in vitro [PDF]

, 2014
This paper was presented at the 4th Micro and Nano Flows Conference (MNF2014), which was held at University College, London, UK. The conference was organised by Brunel University and supported by the Italian Union of Thermofluiddynamics, IPEM, the ...
4th Micro and Nano Flows Conference (MNF2014), Boldock, L, Casbolt, H, Cevans, P, Hsiao, S, Perrault, C, Poitevin, C   +6 more
core  

Long-term outcomes after a strategy of percutaneous coronary intervention of the infarct-related artery with drug-eluting stents or bare metal stents vs medical therapy alone in the Occluded Artery Trial (OAT)

, 2012
Xavier Freixa, Vladimír Džavík, Sandra Forman, James M. Rankin, Christopher E. Buller, Warren J. Cantor, Witold Rużyłło, Harmony R. Reynolds, Gervasio A. Lamas, Judith S. Hochman   +9 more
openalex   +2 more sources